Related Experiment Video

Updated: Apr 15, 2026

Glutamine Flux Imaging Using Genetically Encoded Sensors
10:23

Glutamine Flux Imaging Using Genetically Encoded Sensors

Published on: July 31, 2014

10.1K

Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer

Mohamed Hassanein1, Jun Qian1, Megan D Hoeksema1

  • 1Thoracic Program, Vanderbilt-Ingram Comprehensive Cancer Center and Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, TN.

International Journal of Cancer
|March 31, 2015
PubMed

Insights

Solute carrier family A1 member 5 (SLC1A5) is crucial for glutamine uptake in non-small cell lung cancer (NSCLC). Targeting SLC1A5 inhibits tumor growth and identifies it as a prognostic biomarker for NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Solute carrier family A1 member 5 (SLC1A5) is identified as the primary glutamine transporter in non-small cell lung cancer (NSCLC).
  • SLC1A5 plays a role in modulating cell growth and oxidative stress within NSCLC.
  • Understanding SLC1A5's function is key to developing novel therapeutic strategies and biomarkers for NSCLC.

Purpose of the Study:

  • To evaluate SLC1A5 as a potential therapeutic target in NSCLC.
  • To assess SLC1A5 as a candidate biomarker for predicting survival and treatment response in NSCLC.
  • To investigate the effects of SLC1A5 inhibition on cancer cell biology.

Main Methods:

  • SLC1A5 targeting was performed using RNA interference and a small molecule inhibitor (gamma-l-glutamyl-p-nitroanilide, GPNA) in NSCLC and human bronchial cell lines.
  • Effects on cell growth, glutamine uptake, ATP levels, autophagy, and apoptosis were analyzed.
  • Tumor growth was assessed in NSCLC xenograft models.
  • Prognostic value was evaluated using multivariate Cox proportional hazards analysis on mRNA expression and immunohistochemistry data from 207 NSCLC patients.

Main Results:

  • Genetic or pharmacological inactivation of SLC1A5 reduced glutamine consumption and inhibited cell growth in a subset of NSCLC cell lines.
  • SLC1A5 targeting induced autophagy and apoptosis in these cell lines.
  • Targeting SLC1A5 significantly decreased tumor growth in NSCLC xenografts.
  • Increased SLC1A5 mRNA expression correlated with shorter overall survival (p=0.01).
  • SLC1A5 protein expression showed significant prognostic value in both univariate (p<0.0001) and multivariate (p=0.04) analyses.

Conclusions:

  • SLC1A5 is a critical glutamine transporter in NSCLC, influencing cell growth and survival.
  • Targeting SLC1A5 presents a promising therapeutic strategy for glutamine-dependent NSCLC.
  • SLC1A5 serves as a valuable prognostic biomarker for predicting patient survival in NSCLC.
Keywords:
biomarkerglutamine transporterslung cancer

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer08:37

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer

Published on: November 15, 2024

859

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
28.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
71
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
78
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
158